{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:32:57Z","timestamp":1791498777914,"version":"4.3.4"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pregnant subjects suffer disproportionate morbidity and mortality from several viral infections, yet remain routinely excluded from antiviral and immunomodulatory clinical trials. The evidence base used for treatment selection is therefore scattered across small cohort studies, post-marketing registries, case series, and indirect data from nonpregnant populations. An umbrella review may be useful in systematically examining the range, quality, and coherence of evidence for safe and efficacious antiviral and immune-based interventions during pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To synthesise evidence from systematic reviews and large observational studies assessing pregnancy safety and clinical outcomes of antiviral and immune-based treatments for non-congenital viral infections (e.g., influenza, Coronavirus disease 2019 (COVID-19), Monkey pox(mpox), herpes simplex virus (HSV), varicella-zoster virus (VZV), hepatitis B virus (HBV) and hepatitis C virus (HCV), Human Immunodeficiency Virus (HIV), and other viruses).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was conducted as an umbrella review of systematic reviews and large pregnancy cohort studies following PRIOR and PRISMA-2020 reporting guidelines. We searched MEDLINE, Embase, Cochrane Library, and CINAHL from inception to December 2025 for systematic reviews and high-quality pregnancy cohorts regarding pharmacologic management of viral infections in pregnancy. Data were extracted on maternal outcomes, fetal\/neonatal outcomes, and antiviral\/immune-therapy safety signals. The quality was evaluated with AMSTAR-2 and GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-three eligible reviews and 27 pregnancy cohorts were incorporated. Robust evidence demonstrates the safety of oseltamivir against influenza, acyclovir\/valacyclovir for HSV\/VZV, tenofovir disoproxil fumarate (TDF) and lamivudine to treat HBV, and combination ART for HIV. Nirmatrelvir\/ritonavir (Paxlovid) and remdesivir evidence in COVID-19 pregnancy is somewhat modest but increasingly encouraging, with no excess important congenital anomalies. For tecovirimat in mpox and ribavirin alternatives for viral hemorrhagic fevers, data are still very scarce. No antiviral yielded consistent signals across therapies of teratogenicity; however, the vast majority of evidence is observational with moderate-to-low certainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Substantial heterogeneity and continued trial exclusion from pregnant subjects reduce antiviral evidence; however, various treatments offer favourable safety profiles. There are pressing omissions in mpox, new COVID-19 antivirals, and emerging pathogens. Therefore, further development of dedicated pregnancy pharmacokinetic studies and parallel-trial inclusion strategies is urgently needed to further enhance evidence-based care for viral infection in pregnant women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1762439","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:23:03Z","timestamp":1773984183000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of major antiviral and immune therapies in pregnancy for maternal viral infections: evidence synthesis of maternal and neonatal outcomes"],"prefix":"10.3389","volume":"13","author":[{"given":"Sirwan","family":"Sleman","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, University of Sulaimani","place":["Sulaymaniyah, Iraq"]},{"name":"Nursing Department, National Institute of Technology","place":["Sulaymaniyah, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omed I.","family":"Abid","sequence":"additional","affiliation":[{"name":"Sulaimani Veterinary Directorate, Sulaimani Veterinary Laboratory","place":["Sulaymaniyah, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barham J.","family":"Abdullah","sequence":"additional","affiliation":[{"name":"Sulaimani Veterinary Directorate, Sulaimani Veterinary Laboratory","place":["Sulaymaniyah, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaniar A.","family":"Abass","sequence":"additional","affiliation":[{"name":"Sulaimani Veterinary Directorate, Sulaimani Veterinary Laboratory","place":["Sulaymaniyah, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood B.","family":"Ameen","sequence":"additional","affiliation":[{"name":"Sulaimani Veterinary Directorate, Sulaimani Veterinary Laboratory","place":["Sulaymaniyah, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.clp.2019.02.009","article-title":"Treatment of viral infections during pregnancy","volume":"46","author":"Rogan","year":"2019","journal-title":"Clin Perinatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"20809","DOI":"10.1038\/s41598-025-09283-6","article-title":"Use of antiviral medications during pregnancy and the likelihood of preeclampsia in a population-based register study","volume":"15","author":"Zancanaro","year":"2025","journal-title":"Sci Rep"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e1002160","DOI":"10.1371\/journal.pmed.1002160","article-title":"Pregnancy-associated changes in pharmacokinetics: a systematic review","volume":"13","author":"Pariente","year":"2016","journal-title":"PLoS Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(09)61304-0","article-title":"H1N1 2009 influenza virus infection during pregnancy in the USA","volume":"374","author":"Jamieson","year":"2009","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/bdr2.1566","article-title":"Oseltamivir use in pregnancy: risk of birth defects, preterm delivery, and small for gestational age infants","volume":"111","author":"Chambers","year":"2019","journal-title":"Birth Defects Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/bdr2.1563","article-title":"Oseltamivir exposure in pregnancy and the risk of specific birth defects","volume":"111","author":"Van Bennekom","year":"2019","journal-title":"Birth Defects Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/s0002-9378(98)70176-0","article-title":"Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy","volume":"179","author":"Kimberlin","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/hep.28302","article-title":"Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis","volume":"63","author":"Brown","year":"2016","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s11901-024-00659-2","article-title":"Management of hepatitis B in pregnancy","volume":"23","author":"Rios","year":"2024","journal-title":"Curr Hepatol Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1093\/jpids\/piae070","article-title":"Overview of hepatitis C in pregnancy: screening, management, and treatment","volume":"13","author":"Rios","year":"2024","journal-title":"J Pediatr Infect Diseases Soc"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1093\/cid\/ciaa805","article-title":"Pregnancy outcomes of women conceiving on antiretroviral therapy (ART) compared to those commenced on ART during pregnancy","volume":"73","author":"Theron","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1056\/NEJMoa991159","article-title":"Antiretroviral therapy during pregnancy and the risk of an adverse outcome","volume":"346","author":"Tuomala","year":"2002","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jama.2023.5076","article-title":"Antiretroviral treatment of HIV\/AIDS during pregnancy","volume":"329","author":"Eke","year":"2023","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1056\/NEJMoa1108275","article-title":"Three postpartum antiretroviral regimens to prevent intrapartum HIV infection","volume":"366","author":"Nielsen-Saines","year":"2012","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1056\/NEJMp2410045","article-title":"Mpox in pregnancy - risks, vertical transmission, prevention, and treatment","volume":"391","author":"Nachega","year":"2024","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.placenta.2022.10.002","article-title":"Common pathways targeted by viral hemorrhagic fever viruses to infect the placenta and increase the risk of stillbirth","volume":"141","author":"Coler","year":"2022","journal-title":"Placenta"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ajog.2020.03.021","article-title":"Coronavirus disease 2019 (COVID-19) pandemic and pregnancy","volume":"222","author":"Dashraath","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.15585\/mmwr.mm6925a1","article-title":"Characteristics of women of reproductive age with COVID-19","volume":"69","author":"Ellington","year":"2020","journal-title":"MMWR"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ajog.2021.08.054","article-title":"An update on COVID-19 and pregnancy","volume":"226","author":"Jamieson","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10928-020-09687-z","article-title":"Challenges in conducting clinical research studies in pregnant women","volume":"47","author":"McKiever","year":"2020","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"104721","DOI":"10.1016\/j.antiviral.2020.104721","article-title":"Prevention and treatment of neonatal herpes simplex virus infection","volume":"176","author":"Samies","year":"2020","journal-title":"Antivir Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/liv.15873","article-title":"Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: maternal ALT trajectory and infant outcomes","volume":"44","author":"Chen","year":"2024","journal-title":"Liver Int"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3904\/kjim.2018.465","article-title":"Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis","volume":"36","author":"Lee","year":"2019","journal-title":"Korean J Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"100375","DOI":"10.1016\/j.ijregi.2024.100375","article-title":"Pregnant women with chronic hepatitis B virus infection at the assessment of tenofovir disoproxil fumarate prescription: baseline characteristics of a prospective cohort study in Vietnam","volume":"11","author":"Pham","year":"2024","journal-title":"IJID Regions"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1056\/NEJMoa1905230","article-title":"Neural-tube defects and antiretroviral treatment regimens in Botswana","volume":"381","author":"Zash","year":"2019","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/AOG.0000000000005471","article-title":"Oral Nirmatrelvir\u2013ritonavir use and clinical outcomes in pregnant patients with coronavirus disease 2019 (COVID-19)","volume":"143","author":"Toure","year":"2023","journal-title":"Obstet Gynecol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1002\/jmv.26986","article-title":"Remdesivir for the treatment of COVID-19 in pregnancy","volume":"93","author":"Lampejo","year":"2021","journal-title":"J Med Virol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/jac\/dkab311","article-title":"A review of remdesivir for COVID-19 in pregnancy and lactation","volume":"77","author":"Jorgensen","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e08835","DOI":"10.1016\/j.heliyon.2022.e08835","article-title":"Remdesivir for pregnancy: a systematic review of antiviral therapy for COVID-19","volume":"8","author":"Budi","year":"2022","journal-title":"Heliyon"},{"key":"ref31","volume-title":"Monkeypox Clinical Care and Treatment During Pregnancy","year":"2025"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.21106\/ijma.594","article-title":"Monkeypox in pregnancy: susceptibility, maternal and fetal outcomes, and one health concept","volume":"11","author":"Najimudeen","year":"2022","journal-title":"Int J Matern Child Health AIDS"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e3725","DOI":"10.1371\/journal.pone.0003725","article-title":"Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin","volume":"3","author":"Gowen","year":"2008","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e28548","DOI":"10.1002\/jmv.28548","article-title":"Investigating the effect of ribavirin treatment on genetic mutations in Crimean-Congo haemorrhagic fever virus (CCHFV) through next-generation sequencing","volume":"95","author":"D'Addiego","year":"2023","journal-title":"J Med Virol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ajog.2013.01.015","article-title":"Infant outcomes among pregnant women who used oseltamivir for treatment of influenza during the H1N1 epidemic","volume":"208","author":"Xie","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2165\/11536370-000000000-00000","article-title":"Safety of oseltamivir in pregnancy","volume":"33","author":"Donner","year":"2010","journal-title":"Drug Saf"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/cid\/cit750","article-title":"Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010\u20132011 and 2011\u20132012 influenza seasons","volume":"58","author":"Thompson","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in pregnancy","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1503\/cmaj.090866","article-title":"Safety of neuraminidase inhibitors against novel influenza a (H1N1) in pregnant and breastfeeding women","volume":"181","author":"Tanaka","year":"2009","journal-title":"CMAJ"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"ofab138","DOI":"10.1093\/ofid\/ofab138","article-title":"Clinical effectiveness and safety of antivirals for influenza in pregnancy","volume":"8","author":"Chow","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3390\/vaccines12070782","article-title":"Safety and efficacy of antiviral drugs and vaccines in pregnant women: insights from physiologically based pharmacokinetic modeling and integration of viral infection dynamics","volume":"12","author":"Costa","year":"2024","journal-title":"Vaccine"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/cid\/ciy737","article-title":"Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010\u20132016","volume":"68","author":"Thompson","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1001\/jama.2010.1206","article-title":"Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects","volume":"304","author":"Pasternak","year":"2010","journal-title":"JAMA"},{"key":"ref45","first-page":"427","article-title":"Safety of antiviral medication for the treatment of herpes during pregnancy","volume":"57","author":"Kang","year":"2011","journal-title":"Can Fam Physician"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"9377","DOI":"10.3748\/wjg.v19.i48.9377","article-title":"Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection","volume":"19","author":"Celen","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref47","first-page":"154","article-title":"A review of antiviral use for the treatment of chronic hepatitis B virus infection in pregnant women","volume":"13","author":"Jaffe","year":"2017","journal-title":"Gastroenterol Hepatol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S1473-3099(20)30586-7","article-title":"Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis","volume":"21","author":"Funk","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejogrb.2022.07.009","article-title":"Efficacy and safety of tenofovir disoproxil fumarate or telbivudine used throughout pregnancy for the prevention of mother-to-child transmission of hepatitis B virus: a cohort study","volume":"276","author":"Li","year":"2022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1016\/S2352-3018(23)00061-9","article-title":"Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"10","author":"Chinula","year":"2023","journal-title":"Lancet HIV"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(21)00314-7","article-title":"Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010\/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"397","author":"Lockman","year":"2021","journal-title":"Lancet"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3390\/pathogens13121055","article-title":"Evaluating drug interaction risks: Nirmatrelvir & Ritonavir Combination (PAXLOVID\u00ae) with concomitant medications in real-world clinical settings","volume":"13","author":"Zatovka\u0148ukov\u00e1","year":"2024","journal-title":"Pathogens"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.jiph.2023.10.007","article-title":"Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the omicron wave of the coronavirus disease 2019 pandemic","volume":"16","author":"Lin","year":"2023","journal-title":"J Infect Public Health"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/AOG.0000000000004900","article-title":"Short-term pregnancy outcomes after Nirmatrelvir-ritonavir treatment for mild-to-moderate coronavirus disease 2019 (COVID-19)","volume":"140","author":"Loza","year":"2022","journal-title":"Obstet Gynecol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e2244141","DOI":"10.1001\/jamanetworkopen.2022.44141","article-title":"Analysis of clinical outcomes of pregnant patients treated with Nirmatrelvir and ritonavir for acute SARS-CoV-2 infection","volume":"5","author":"Garneau","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/cid\/ciae580","article-title":"COVID-19 antiviral medication use among pregnant and recently pregnant US outpatients","volume":"80","author":"Regan","year":"2025","journal-title":"Clin Infect Dis"},{"key":"ref57","first-page":"243","article-title":"The efficacy and safety of monoclonal antibody treatments against COVID-19: a systematic review and meta-analysis of randomized clinical trials","volume":"55","author":"Wafa","year":"2023","journal-title":"Acta Med Indones"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41372-023-01734-0","article-title":"A narrative review of COVID-19 vaccination in pregnancy and breastfeeding","volume":"44","author":"Devera","year":"2023","journal-title":"J Perinatol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0140-6736(22)01063-7","article-title":"Guidelines for pregnant individuals with monkeypox virus exposure","volume":"400","author":"Dashraath","year":"2022","journal-title":"Lancet (London, England)"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1473-3099(23)00054-3","article-title":"Treatment and prevention of mpox in pregnant people and young children","volume":"23","author":"Khalil","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3390\/v17040456","article-title":"Vaccines and antiviral therapies for Mpox virus in pregnant and breastfeeding women: efficacy and maternal\u2013child outcomes","volume":"17","author":"Imran","year":"2025","journal-title":"Viruses"},{"key":"ref62","volume-title":"Infections and Pregnancy","author":"Goh","year":"2022"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s40475-019-00194-x","article-title":"Viral hemorrhagic fevers in pregnant women and the vaccine landscape: comparisons between yellow fever, Ebola, and Lassa fever","volume":"6","author":"Krubiner","year":"2019","journal-title":"Curr Trop Med Rep"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"107095","DOI":"10.1016\/j.ijantimicag.2024.107095","article-title":"Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the omicron era: a prospective cohort study","volume":"63","author":"Calder\u00f3n-Parra","year":"2024","journal-title":"Int J Antimicrob Agents"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1762439\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:23:06Z","timestamp":1773984186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1762439\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":64,"alternative-id":["10.3389\/fmed.2026.1762439"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1762439","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"article-number":"1762439"}}